Inspire Comes Up Short In Phase III Study; Stock Falls 73 Percent
By Kim Coghill
Thursday, January 17, 2002
Inspire Pharmaceuticals Inc. said its not likely that the first Phase III trial of its lead product for dry eye will reach its endpoints. The negative news sent Inspires stock tumbling 73 percent.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.